Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

a first-line randomized phase II/III study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone as part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate similar objective response rates to the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. A total of 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines. The main adverse events associated with pixantrone in clinical trials to date include myelosuppression and alopecia.

About NHL

According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology pro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... -- "Whether it,s our family, our friends, all of ... a single sentence, Dr. Anthony Coyle , senior ... Centers for Therapeutic Innovation (CTI), sums up what ... biopharmaceutical companies. CTI,s unique model allows ... and the National Institutes of Health (NIH) to bridge ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... SILVER SPRING, Md., Dec. 20, 2010 Each year, ... drugs that treat a wide variety of conditions and ... recent significant FDA approvals for generic medications, go to ... notices of new FDA Consumer Updates at: ...
... Inc. today announced the development of software that uses ... assist ophthalmologists and optometrists in diagnosing retinal and optic ... is an imaging technique used to provide ophthalmologists and ... (RNFL) which can help them diagnose diseases like glaucoma. ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2
(Date:3/27/2015)... TX (PRWEB) March 27, 2015 The ... is an essential source of information on and analysis ... US. The population of the US in 2013 amounted ... Growth Rate (CAGR) of 0.8% from 2008. The country’s ... of chronic diseases will help to boost the growth ...
(Date:3/27/2015)... Naples, FL and London, UK (PRWEB) March 27, 2015 ... solution, announced today that it has appointed Sean Fitzgerald, ... the role of Chief Operating Officer and Interim Chief ... Vice President of leading education technology innovator, EverFi, backed ... Eric Schmidt, and Twitter founder Evan Williams. Prior to ...
(Date:3/27/2015)... GrassrootsHealth, an international nonprofit public health ... NOW! vitamin D demonstration project April 7 in the ... (MUSC), and will soon follow with a second phase ... to a minimum of 500 pregnant women at 17 ... service areas. The project will include patient and health ...
(Date:3/27/2015)... 2015 When struck with the aftermath ... know where to begin. The latest eBook released ... attorney, offers accident victims a clear and concise process ... ensure their personal injury claim is seen through to ... first actions that should be taken immediately following the ...
(Date:3/27/2015)... Trail mix is the perfect, healthy snack ... hikes and during the game! It’s portable, lightweight and provides ... to introduce a new line of specialty trail mixes that ... flavorful selections packed with nutritious, 100% all natural ingredients. , ... that add protein and fiber to your diet and boost ...
Breaking Medicine News(10 mins):Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2
... Older adults who don,t get enough vitamin D ... at increased risk of developing mobility limitations and disability, according ... "This is one of the first studies to look at ... mobility limitations or disability in older adults," said lead author ...
... been approved since March 2011 in men with metastatic ... with hormone blockers and have already been pre-treated with ... pursuant to the "Act on the Reform of the ... Quality and Efficiency in Health Care (IQWiG) examined whether ...
... of Physicians (ACP), the second-largest physician group in the United ... aims to prevent one million heart attacks and strokes in ... Empowering Americans to make healthy choices such as preventing ... can reduce the number of people who need medical treatment ...
... Vitamin D deficiency is not healthy. However, new research from ... level of the essential vitamin is not good either. The ... results have just been published in the reputed scientific ... is instrumental in helping calcium reach our bones, thus lessening ...
... aspirin and other similar painkillers may help protect against ... a peer-reviewed journal of the American Cancer Society, the ... to the benefits of these commonly used medications. ... NSAIDs, which include aspirin, ibuprofen, and naproxen, as well ...
... Aggressive efforts to lower blood pressure in people with ... a new study The research shows that there ... with diabetes in the U.S. Department of Veterans Affairs, with ... controlled and 94 percent getting appropriate BP treatment. ...
Cached Medicine News:Health News:Older adults may need more vitamin D to prevent mobility difficulties 2Health News:Cabazitaxel can offer an advantage in certain patients 2Health News:Cabazitaxel can offer an advantage in certain patients 3Health News:ACP joins Million Hearts to help save lives from preventable heart attacks and strokes 2Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Commonly used painkillers may protect against skin cancer 2Health News:1 size doesn't fit all when treating blood pressure in people with diabetes, VA/U-M study suggests 2Health News:1 size doesn't fit all when treating blood pressure in people with diabetes, VA/U-M study suggests 3
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... SEDIPLAST® is a completely closed system ... laboratory personnel from the risk associated ... uniquely designed erythrocyte sedimentation rate test ... convenience as well as reliable and ...
... Unlike other ESR products, SEDIPLAST® is ... design features to protect laboratory personnel ... handling. SEDIPLAST® is a uniquely designed ... provides greater safety and convenience as ...
... The use of guaiac as ... of blood is based on ... present in guaiac to quinones, ... a blue color. If blood ...
Medicine Products: